In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $9.74 in the last session, up 1.99% from day before closing price of $9.55. In other words, the price has increased by $1.99 from its previous closing price. On the day, 1.22 million shares were traded. PHAT stock price reached its highest trading level at $10.13 during the session, while it also had its lowest trading level at $9.51.
Ratios:
We take a closer look at PHAT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 21 ’25 when Topper James N bought 3,780 shares for $3.86 per share. The transaction valued at 14,609 led to the insider holds 59,403 shares of the business.
Topper James N bought 6,300 shares of PHAT for $20,919 on May 14 ’25. The Director now owns 55,623 shares after completing the transaction at $3.32 per share. On May 13 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,120 shares for $3.16 each. As a result, the insider paid 3,543 and bolstered with 49,323 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 679989248 and an Enterprise Value of 1032310336. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.31. Its current Enterprise Value per Revenue stands at 12.611 whereas that against EBITDA is -3.614.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.35, which has changed by -0.09898245 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $19.71, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 73.30%, while the 200-Day Moving Average is calculated to be 10.40%.
Shares Statistics:
According to the various share statistics, PHAT traded on average about 2.78M shares per day over the past 3-months and 2012820 shares per day over the past 10 days. A total of 69.64M shares are outstanding, with a floating share count of 37.85M. Insiders hold about 45.79% of the company’s shares, while institutions hold 47.30% stake in the company. Shares short for PHAT as of 1749772800 were 11038334 with a Short Ratio of 3.97, compared to 1747267200 on 11177554. Therefore, it implies a Short% of Shares Outstanding of 11038334 and a Short% of Float of 26.38.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Phathom Pharmaceuticals Inc (PHAT) in the stock market.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.34 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.45 and -$3.45 for the fiscal current year, implying an average EPS of -$2.93. EPS for the following year is -$0.59, with 5.0 analysts recommending between $0.34 and -$2.32.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $35.65M. It ranges from a high estimate of $37M to a low estimate of $32.7M. As of the current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $7.32MFor the next quarter, 7 analysts are estimating revenue of $42.62M. There is a high estimate of $47.37M for the next quarter, whereas the lowest estimate is $37.4M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $172.6M, while the lowest revenue estimate was $146.9M, resulting in an average revenue estimate of $159.6M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $328.54M in the next fiscal year. The high estimate is $381.1M and the low estimate is $270M.
